Tristel plc Earnings Call Highlights Growth Momentum

Tristel plc ((GB:TSTL)) has held its Q2 earnings call. Read on for the main highlights of the call.

Tristel plc’s latest earnings call struck an upbeat tone as management showcased record revenue, widening margins and strong cash generation, all while remaining debt-free. Executives acknowledged pockets of weakness in China and near-term cost pressure from investment and insourcing, but argued that accelerating U.S. traction and European strength leave the group well positioned for sustained growth.

Record Revenue Growth

Group revenue climbed 14% year-on-year to a record £25.6m in the first half of FY2026, with constant-currency growth of 12.4% underscoring the underlying momentum. Both the U.K. business, which expanded nearly 13%, and international markets contributed, reflecting broad-based demand for the company’s infection prevention solutions.

Strong Profitability and Margin Expansion

Adjusted profit before tax rose 11% to £5.5m, while adjusted EBITDA increased 17%, translating into adjusted earnings per share of 9.36p. The adjusted EBITDA margin reached 29%, comfortably ahead of management’s minimum 25% target and highlighting operating leverage despite higher investment across the business.

Robust Cash Position and Debt-Free Balance Sheet

Operating cash generation was £6.7m in the half, lifting cash and deposits to £13.3m and leaving the company with no debt on its balance sheet. This financial strength underpins a progressive dividend approach and gives Tristel ample firepower to fund expansion, clinical programs and digital initiatives without stretching the balance sheet.

Significant U.S. Commercial Momentum

In the U.S., Tristel ULT in-market sales are approaching $1m, with the company earning royalties and a growing net profit contribution from partners. Procedure volumes tripled year-on-year to around 320,000 in the first half, and management expects in-market sales to exceed $2m by year-end as the installed base and usage continue to build.

New Products and Distribution Partnerships

The launch of Tristel OPH in the U.S. generated $88k of first-half revenue, ahead of initial expectations, with local manufacturing handled by Parker Laboratories. New distribution agreements with Parker, Medline, Henry Schein, Cardinal Health and leading eyecare groups are expected to widen access, with current gross margins in line with group targets and scope to improve as volumes scale.

Clinical and Regulatory Validation

Tristel ULT has been referenced in four influential standards and guidelines for high-level disinfection of ultrasound probes, while an independent assessment by ECRI is underway. More than 1,200 probes have been validated as compatible, and a multicenter OPH study is progressing, all of which should support clinician confidence and drive adoption.

Geographic Recovery and European Strength

European performance remained a bright spot, with France and Italy each growing about 13% on the back of market recovery and tender wins. Other European territories also delivered double-digit growth, and the company plans targeted hiring in Germany, France, Italy, the Middle East and Asia to further accelerate regional sales.

Strategic Investments in People and Digital Tools

Management outlined a ramp-up in commercial and clinical resources, with plans to add 13 commercial heads, including nine salespeople and four clinical specialists, alongside a new Chief Medical Officer and clinical portfolio leads. The company is also investing in digital tools such as its 3T platform, a web shop roll-out and an internal AI agent to deepen recurring revenue and sharpen sales execution.

Operational Improvements and Cost Savings

Tristel has brought wipes production in-house, a move that temporarily weighs on reported margins but is expected to deliver around £300k of annualised savings once prior third-party inventory is cleared in the second half. Efficiency gains are already visible, with net working capital down to 15% of annualised revenue and return on capital employed running at 25%.

Execution Against Clear Financial Targets

Management reiterated its commitment to double-digit annual revenue growth from FY2025 to FY2030 and a minimum adjusted EBITDA margin of 25%. With current results showing 14% top-line expansion and a 29% adjusted EBITDA margin, executives argued that the business is tracking ahead of its margin commitments while executing on its long-term growth plan.

China and APAC Weakness

Not all regions are firing, with Asia-Pacific growing just 0.3% in the half, held back by notable weakness in China. Management cited a broader market slowdown, customer bankruptcies and changes in local policy and healthcare financing, which have dampened demand from private hospitals and offset stronger performance elsewhere.

Margin Pressure and One-Off Charges

Group gross margin edged down to 81% from 82% a year earlier, mainly due to higher depreciation and staffing costs linked to insourcing wipes production. The period also absorbed a one-off £300k write-off of intangible assets, which management framed as a contained impact within an otherwise robust margin profile.

Higher Operating Costs from Investment and Transition

Administration, distribution and depreciation and amortisation expenses all moved higher as Tristel stepped up spending on sales and marketing, insourcing assets and leadership succession. While these choices weigh on near-term profitability, management emphasised that they underpin future growth and smoother executive transitions rather than signalling structural cost issues.

U.S. Rollout Pace and Recruitment Bottlenecks

Executives acknowledged that the initial commercial build-out in the U.S. was slower than anticipated and that hiring high-calibre sales talent is taking longer than hoped. These recruitment challenges may temper the speed of near-term acceleration, even as lead pipelines, procedure growth and distributor relationships point to a steadily improving U.S. trajectory.

Dividend Policy and Interim Payout

The interim dividend was held flat at 5.68p, a neutral outcome for income investors who might have expected a rise in line with earnings. Management nonetheless reiterated its intention to grow the full-year dividend per share, supported by strong cash generation and the broader progressive dividend framework.

Forward-Looking Guidance and Growth Outlook

Looking ahead, Tristel reaffirmed targets for double-digit revenue growth through FY2030 and at least a 25% adjusted EBITDA margin, supported by current metrics of a 21% PBT margin and 29% EBITDA margin. U.S. milestones include pushing Tristel ULT in-market sales beyond $2m this year, scaling OPH from its $88k base and capturing a sizeable VISICLEAN procedure opportunity, while cost savings from insourcing and new commercial hires are expected to further support earnings.

Tristel’s earnings call painted the picture of a company using a strong balance sheet and rising profits to fund a disciplined global expansion, led by the U.S. and Europe. While China and higher operating costs present near-term challenges, the combination of clinical validation, growing procedure volumes and clear financial targets left management and investors aligned on a constructive long-term growth story.